Erenumab

from Wikipedia, the free encyclopedia

Erenumab (trade name Aimovig ) is a monoclonal antibody that targets the calcitonin gene-related peptide receptor (CGRPR) . It was approved in 2018, initially in the USA, as the first monoclonal antibody for the prophylactic treatment of migraines . In the same year it was also approved in Switzerland, the EU and Canada. The drug is produced by the US biotechnology company Amgen .

Web links

AKDAE : Monoclonal antibodies for the prophylaxis of migraines - Erenumab (Aimovig), Galcanezumab (Emgality) and Fremanezumab (Ajovy) - change if you do not respond?

Individual evidence

  1. ↑ New preventive migraine drug erenumab (Aimovig) approved by FDA (at www.schmerzklinik.de) ( Memento from June 25, 2018 in the Internet Archive )
  2. ↑ Novartis receives approval in Canada for the migraine drug Aimovig (at www.finanzen.ch)